MRFRの分析によると、在宅がん検査の市場規模は2022年に2.37(10億米ドル)と推定されました。この市場は、2023年の2.75 (10億ドル) から2032年までに10.8 (10億ドル) に成長し、予測期間 (2024-2032) のCAGRは約16.4% になると予想されます。
目次
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. AT-HOME CANCER TESTING MARKET, BY TEST TYPE (USD BILLION)
6.1. Genetic Testing
6.2. Biomarker Testing
6.3. Immunological Testing
6.4. Cell-free DNA Testing
7. AT-HOME CANCER TESTING MARKET, BY SAMPLE TYPE (USD BILLION)
7.1. Blood Sample
7.2. Saliva Sample
7.3. Urine Sample
7.4. Tissue Sample
8. AT-HOME CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL (USD BILLION)
8.1. Online Pharmacies
8.2. Retail Pharmacies
8.3. Direct-to-Consumer
9. AT-HOME CANCER TESTING MARKET, BY END USER (USD BILLION)
9.1. Individuals
9.2. Healthcare Professionals
9.3. Research Institutions
10. AT-HOME CANCER TESTING MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the At-Home Cancer Testing Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the At-Home Cancer Testing Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. 23andMe
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. PathAI
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. Guardant Health
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. Egenomics
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. Quanterix
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. NantHealth
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. Oncocyte
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. Genomic Health
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. Exact Sciences
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Myriad Genetics
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Freenome
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Invitae
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. CancerIQ
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. GRAIL
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
12.15. Thermo Fisher Scientific
12.15.1. Financial Overview
12.15.2. Products Offered
12.15.3. Key Developments
12.15.4. SWOT Analysis
12.15.5. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 3. NORTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 4. NORTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 5. NORTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 6. NORTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 7. US AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 8. US AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 9. US AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 10. US AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 11. US AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 12. CANADA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 13. CANADA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 14. CANADA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 15. CANADA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 16. CANADA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 17. EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 18. EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 19. EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 20. EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 21. EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 22. GERMANY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 23. GERMANY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 24. GERMANY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 25. GERMANY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 26. GERMANY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 27. UK AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 28. UK AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 29. UK AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 30. UK AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 31. UK AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 32. FRANCE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 33. FRANCE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 34. FRANCE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 35. FRANCE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 36. FRANCE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 37. RUSSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 38. RUSSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 39. RUSSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 40. RUSSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 41. RUSSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 42. ITALY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 43. ITALY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 44. ITALY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 45. ITALY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 46. ITALY AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 47. SPAIN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 48. SPAIN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 49. SPAIN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 50. SPAIN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 51. SPAIN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 52. REST OF EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 53. REST OF EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 54. REST OF EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 55. REST OF EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 56. REST OF EUROPE AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 57. APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 58. APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 59. APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 60. APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 61. APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 62. CHINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 63. CHINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 64. CHINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 65. CHINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 66. CHINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 67. INDIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 68. INDIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 69. INDIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 70. INDIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 71. INDIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 72. JAPAN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 73. JAPAN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 74. JAPAN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 75. JAPAN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 76. JAPAN AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 77. SOUTH KOREA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 78. SOUTH KOREA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 79. SOUTH KOREA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 80. SOUTH KOREA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 81. SOUTH KOREA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 82. MALAYSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 83. MALAYSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 84. MALAYSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 85. MALAYSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 86. MALAYSIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 87. THAILAND AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 88. THAILAND AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 89. THAILAND AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 90. THAILAND AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 91. THAILAND AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 92. INDONESIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 93. INDONESIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 94. INDONESIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 95. INDONESIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 96. INDONESIA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 97. REST OF APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 98. REST OF APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 99. REST OF APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 100. REST OF APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 101. REST OF APAC AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 102. SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 103. SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 104. SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 105. SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 106. SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 107. BRAZIL AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 108. BRAZIL AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 109. BRAZIL AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 110. BRAZIL AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 111. BRAZIL AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 112. MEXICO AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 113. MEXICO AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 114. MEXICO AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 115. MEXICO AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 116. MEXICO AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 117. ARGENTINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 118. ARGENTINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 119. ARGENTINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 120. ARGENTINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 121. ARGENTINA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 127. MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 128. MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 129. MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 130. MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 131. MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 132. GCC COUNTRIES AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 133. GCC COUNTRIES AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 134. GCC COUNTRIES AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 135. GCC COUNTRIES AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 136. GCC COUNTRIES AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 137. SOUTH AFRICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 138. SOUTH AFRICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 139. SOUTH AFRICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 140. SOUTH AFRICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 141. SOUTH AFRICA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 142. REST OF MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 143. REST OF MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY SAMPLE TYPE, 2019-2032 (USD BILLIONS)
TABLE 144. REST OF MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLIONS)
TABLE 145. REST OF MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 146. REST OF MEA AT-HOME CANCER TESTING MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP
LIST OF FIGURES
FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA AT-HOME CANCER TESTING MARKET ANALYSIS
FIGURE 3. US AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 4. US AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 5. US AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 6. US AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 7. US AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 9. CANADA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 10. CANADA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 11. CANADA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 12. CANADA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE AT-HOME CANCER TESTING MARKET ANALYSIS
FIGURE 14. GERMANY AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 15. GERMANY AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 16. GERMANY AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 17. GERMANY AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 18. GERMANY AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 20. UK AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 21. UK AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 22. UK AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 23. UK AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 25. FRANCE AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 26. FRANCE AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 27. FRANCE AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 28. FRANCE AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 30. RUSSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 31. RUSSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 32. RUSSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 33. RUSSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 35. ITALY AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 36. ITALY AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 37. ITALY AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 38. ITALY AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 40. SPAIN AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 41. SPAIN AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 42. SPAIN AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 43. SPAIN AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 45. REST OF EUROPE AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 46. REST OF EUROPE AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 47. REST OF EUROPE AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 48. REST OF EUROPE AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC AT-HOME CANCER TESTING MARKET ANALYSIS
FIGURE 50. CHINA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 51. CHINA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 52. CHINA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 53. CHINA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 54. CHINA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 56. INDIA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 57. INDIA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 58. INDIA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 59. INDIA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 61. JAPAN AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 62. JAPAN AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 63. JAPAN AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 64. JAPAN AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 66. SOUTH KOREA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 67. SOUTH KOREA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 68. SOUTH KOREA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 69. SOUTH KOREA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 71. MALAYSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 72. MALAYSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 73. MALAYSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 74. MALAYSIA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 76. THAILAND AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 77. THAILAND AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 78. THAILAND AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 79. THAILAND AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 81. INDONESIA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 82. INDONESIA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 83. INDONESIA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 84. INDONESIA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 86. REST OF APAC AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 87. REST OF APAC AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 88. REST OF APAC AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 89. REST OF APAC AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA AT-HOME CANCER TESTING MARKET ANALYSIS
FIGURE 91. BRAZIL AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 92. BRAZIL AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 93. BRAZIL AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 94. BRAZIL AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 95. BRAZIL AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 97. MEXICO AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 98. MEXICO AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 99. MEXICO AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 100. MEXICO AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 102. ARGENTINA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 103. ARGENTINA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 104. ARGENTINA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 105. ARGENTINA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 107. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 108. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 109. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 110. REST OF SOUTH AMERICA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA AT-HOME CANCER TESTING MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 113. GCC COUNTRIES AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 114. GCC COUNTRIES AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 115. GCC COUNTRIES AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 116. GCC COUNTRIES AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 118. SOUTH AFRICA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 119. SOUTH AFRICA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 120. SOUTH AFRICA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 121. SOUTH AFRICA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA AT-HOME CANCER TESTING MARKET ANALYSIS BY TEST TYPE
FIGURE 123. REST OF MEA AT-HOME CANCER TESTING MARKET ANALYSIS BY SAMPLE TYPE
FIGURE 124. REST OF MEA AT-HOME CANCER TESTING MARKET ANALYSIS BY DISTRIBUTION CHANNEL
FIGURE 125. REST OF MEA AT-HOME CANCER TESTING MARKET ANALYSIS BY END USER
FIGURE 126. REST OF MEA AT-HOME CANCER TESTING MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF AT-HOME CANCER TESTING MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF AT-HOME CANCER TESTING MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: AT-HOME CANCER TESTING MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: AT-HOME CANCER TESTING MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: AT-HOME CANCER TESTING MARKET
FIGURE 133. AT-HOME CANCER TESTING MARKET, BY TEST TYPE, 2024 (% SHARE)
FIGURE 134. AT-HOME CANCER TESTING MARKET, BY TEST TYPE, 2019 TO 2032 (USD Billions)
FIGURE 135. AT-HOME CANCER TESTING MARKET, BY SAMPLE TYPE, 2024 (% SHARE)
FIGURE 136. AT-HOME CANCER TESTING MARKET, BY SAMPLE TYPE, 2019 TO 2032 (USD Billions)
FIGURE 137. AT-HOME CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
FIGURE 138. AT-HOME CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2019 TO 2032 (USD Billions)
FIGURE 139. AT-HOME CANCER TESTING MARKET, BY END USER, 2024 (% SHARE)
FIGURE 140. AT-HOME CANCER TESTING MARKET, BY END USER, 2019 TO 2032 (USD Billions)
FIGURE 141. AT-HOME CANCER TESTING MARKET, BY REGIONAL, 2024 (% SHARE)
FIGURE 142. AT-HOME CANCER TESTING MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS